Aptose Biosciences (APTOF) furnishes Regulation FD Form 8-K press release

Rhea-AI Filing Summary

Aptose Biosciences Inc. filed a current report on Form 8-K to furnish information under Regulation FD. On December 19, 2025, the company issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The company specifies that, under General Instruction B.2, the press release is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act or automatically incorporated into other securities filings unless specifically referenced.

False000088236100008823612025-12-192025-12-19iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  December 19, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On December 19, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated December 19, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: December 19, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer

FAQ

What did Aptose Biosciences (APTOF) report in this Form 8-K?

The company reported that on December 19, 2025 it issued a press release, which is furnished as Exhibit 99.1 to the Form 8-K under Regulation FD.

Under which item did Aptose Biosciences (APTOF) furnish the press release?

The press release is furnished under Item 7.01, Regulation FD Disclosure.

Is the Aptose Biosciences (APTOF) press release considered filed with the SEC?

No. The company states that, under General Instruction B.2, the Exhibit 99.1 press release is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

What exhibit is included with Aptose Biosciences’ December 19, 2025 Form 8-K?

Exhibit 99.1 is a press release dated December 19, 2025, and Exhibit 104 is the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Aptose Biosciences (APTOF) Form 8-K?

The Form 8-K was signed on behalf of Aptose Biosciences Inc. by William G. Rice, Ph.D., its Chairman, President, and Chief Executive Officer.

Does this Aptose Biosciences (APTOF) Form 8-K include detailed financial results?

The Form 8-K itself does not describe detailed financial results; it primarily furnishes a press release as Exhibit 99.1 under Regulation FD.